Skip to main content

View full-text article in PMC

. 2012 Mar;19(3):401–410. doi: 10.1128/CVI.05544-11

Table 9.

ICS results for PBL samples from patients with PTB and from healthy donors, using three peptides^a

Peptide and cell type	Mean % ± SD		P value
Peptide and cell type	PTB group (n = 19)	Healthy donor group (n = 5)	P value
E6
CD3⁺ CD4⁺ IFN-γ-producing T cells	0.69 ± 0.56	0.04 ± 0.05	0.007
CD3⁺ CD8⁺ IFN-γ-producing T cells	0.59 ± 0.51	0.11 ± 0.02	0.027
E7
CD3⁺ CD4⁺ IFN-γ-producing T cells	0.63 ± 0.67	0.05 ± 0.01	0.004
CD3⁺ CD8⁺ IFN-γ-producing T cells	0.63 ± 0.59	0.14 ± 0.07	0.049
C14
CD3⁺ CD4⁺ IFN-γ-producing T cells	0.80 ± 0.76	0.21 ± 0.07	>0.05
CD3⁺ CD8⁺ IFN-γ-producing T cells	0.59 ± 0.69	0.29 ± 0.09	>0.05

^a

The results suggest that peptides E6 and E7 respond mainly to CD4⁺ T cells of patients with TB and are ideal CD4⁺ T-cell-responsive epitopes.